Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine
Phase 1Terminated 2 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Pancreatic Ductal Adenocarcinoma
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Trial Timeline
Dec 14, 2021 → Jan 15, 2025
NCT ID
NCT04809766About Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine is a phase 1 stage product being developed by Lonza for Metastatic Pancreatic Ductal Adenocarcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04809766. Target conditions include Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Pancreatic Ductal Adenocarcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04809766 | Phase 1 | Terminated |
Competing Products
20 competing products in Metastatic Pancreatic Ductal Adenocarcinoma